Dr. Xiaoqiang Wang (MD., PhD.) is Research Associate and Board Certified Clinical Pathologist in Center of Excellence for Molecular Diagnostics at Peking University Third Hospital, Beijing, China. He accomplished his Ph.D in Molecular Medicine from Laval University (Canada) and MD from Hebei Medical University (China), and he received clinical research training as visitor scholar from University of Washington (USA). Scientifically, He has been interested in developing novel genetic biomarkers to evaluate and monitor the therapy efficacy and potential drug resistance within treatment cycle, meanwhile, proposing combined therapeutic strategy based on genetic biomarkers for cancer, especially hormone dependent cancer such as breast cancer, prostate cancer and ovarian cancer. Technically, He has been interested in developing novel 3D cell culture and Patient Derived Xenograft (PDX) animal model for drug screening and efficacy evaluation. He has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences.

Personalized-Therapeutic-Optimization; Drug screening; Patient Derived Xenograft (PDX).